Asset sale Announced
Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug
US$250m consideration
Announced 31 Jul 2026
Advisers
Neurimmune's royalty interest in AstraZeneca's cliramitug
Target
Not disclosed
Royalty Pharma
Acquirer
- Legal adviser
- Target
- Neurimmune's royalty interest in AstraZeneca's cliramitug
- Acquirer
- Royalty Pharma
- Seller
- Neurimmune
- Buyer based in
- United States
- Seller based in
- Switzerland
- Sector
- Pharma
- Tags
- Pharma, Biotech
In the league tables
Similar deals
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- Teva Pharmaceuticals acquisition of Emalex Biosciences Apr 2026 · US$700m · Pharma
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
